Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
presented by
N
More Tools & Gadgets
F&G: 76
6.339,00 S&P · 18,85 Vola-Index · 117.947,81 BTC · 1,16909 EURUSD
System-State: Number of processed items 52.085 Notifications successully processed since Inception
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US68622V1061
State: 21.07.2025 | 6PM
Do you already know our new terminal view? Click here.
FIGI: BBG00ZQRGW24
OGN
Organon & Co.
GICS: - · Sector: Healthcare · Sub-Sector: Drug Manufacturers - General
NAME
Organon & Co.
ISIN
US68622V1061
TICKER
OGN
MIC
XNYS
REUTERS
OGN.N
BLOOMBERG
OGN US
Wed, 07.05.2025       Organon & Co.
US68622V1061

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Organon & Co. (NYSE: OGN) focused on whether Organon as well as certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have info...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 01.05.2025       Organon & Co.
US68622V1061

The DJS Law Group announces that it is investigating claims on behalf of investors of Organon & Co. (“Organon” or “the Company”) (NYSE: OGN) for violations of the securities laws. INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements and/or failed to disclose information pertinent to investors. A...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 01.05.2025       Organon & Co.
US68622V1061

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Organon & Co. (“Organon” or “the Company”) (NYSE: OGN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclo...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Thu, 01.05.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN) today announced its results for the first quarter ended March 31, 2025. “We have reset our capital allocation priorities to accelerate progress towards deleveraging, enabling a path to achieve a net leverage ratio of below 4.0x by year-end. Over the last year, we have established a leaner, more fit-for-purpose cost structure w...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.04.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN) a global healthcare company with a focus on women’s health, today announced the appointment of Ramona A. Sequeira, President of the Global Portfolio Division at Takeda Pharmaceutical Company, to Organon’s Board of Directors, effective July 1, 2025. Ms. Sequeira will serve on the Board’s Talent Committee. In connection with Ms. ...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.04.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a primary focus on women’s health, will release its first quarter 2025 financial results on May 1, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record approximately $6 million of milestone...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Tue, 01.04.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a deep expertise in biosimilars, today announced that it has acquired from Biogen Inc. (Nasdaq: BIIB) regulatory and commercial rights in the U.S. for TOFIDENCE™, a biosimilar to ACTEMRA®, for intravenous infusion. TOFIDENCE, the first approved tocilizumab biosimilar entrant in the U.S. market,...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Fri, 28.03.2025       Organon & Co.
US68622V1061

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) today announced that the European Medicines Agency (EMA) has validated the marketing authorization application (MAA) for HLX11, an investigational biosimilar of Perjeta® (pertuzumab). Pertuzumab has been approved in various countries and regions in combination with trastuzumab and ch...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Sat, 08.03.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA® (tapinarof) cream, 1% once daily in adults and children 2 years of age and older with atopic dermatitis (AD), also known as eczema. The findings d...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 13.02.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2024. “In 2024 we achieved our third year of constant currency revenue growth and delivered Adjusted EBITDA margin expansion ex-IPR&D,” said Kevin Ali, Organon's chief executive officer. “Our 2025 financial guidance reflects the potential ...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Thu, 23.01.2025       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its fourth quarter and full year 2024 financial results on February 13, 2025, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EST. IPR&D and Milestones Organon does not currently expect to record any milestone expense in...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 19.12.2024       Organon & Co.
US68622V1061

Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a fireside chat at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13th, 2025, at 3:45 p.m. PT. Investors, analysts, members of the media and the general public are invited...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Mon, 16.12.2024       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) has approved VTAMA® (tapinarof) cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in a...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Tue, 05.11.2024       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months the target action date of its review of the supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) cream, 1% as a treatment for ato...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Thu, 31.10.2024       Organon & Co.
US68622V1061

Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2024. "In 2024 our commercial execution has been very strong. Our largest product, Nexplanon, is well positioned to deliver $1 billion of revenue next year and we've added other notable growth drivers with Emgality and most recently, VTAMA," said Kevin Ali, ...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Wed, 30.10.2024       Organon & Co.
US68622V1061

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the US Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for HLX14, an investigational biosimilar of PROLIA/XGEVA (denosumab). This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Mon, 28.10.2024       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, today announced the successful completion of its acquisition of Dermavant Sciences Ltd. from Roivant (NASDAQ: ROIV). Dermavant is a company dedicated to developing and commercializing innovative therapeutic solutions in immuno-der...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Wed, 09.10.2024       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its third quarter 2024 financial results on October 31, 2024, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT. IPR&D and Milestones Organon currently expects that it will record $51 million of milestone expense in the ...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Mon, 30.09.2024       Organon & Co.
US68622V1061

Shanghai Henlius Biotech, Inc. (2696.HK) and Organon (NYSE: OGN) announced that the phase 3 comparative clinical trial for the investigational Perjeta® (pertuzumab) biosimilar HLX11 met the primary endpoint. In 2022, Henlius entered into a license and supply agreement with Organon for the exclusive commercialization rights to two biosimilar candid...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Wed, 18.09.2024       Organon & Co.
US68622V1061

Organon (NYSE: OGN), a global healthcare company with a mission to improve the health of women throughout their lives, and Dermavant Sciences Ltd. announced today that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant (NASDAQ: ROIV) company dedicated to developing and commercializing innovative th...
Read More
Organon & Co.
Technical Analysis Termsheet Terminal
Permalink
Silent Ad
Neogen
Rosen Law Firm Urges Neogen Corporation (NASDAQ: NEOG) Stockholders to Contact the Firm for Information About Their Rights
© BusinessWire
DevStream
DevvStream Completes $10M Initial Funding to Launch $300M Asset-Backed Digital Infrastructure and Sustainability Strategy
© BusinessWire
Addus HomeCare
Addus HomeCare Announces Second Quarter 2025 Earnings Release and Conference Call
© BusinessWire
Summit Bank Group
Summit Bank Announces the Addition of Max Williams to Its Portland Metro Advisory Board
© BusinessWire
Neogen
NEOGEN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Neogen Corporation - NEOG
© BusinessWire
iTeos Therapeutics
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
© BusinessWire
Frontdoor
Frontdoor Announces Sponsorship with Non-Profit to Provide Job Training for Military Veterans
© BusinessWire
Weave Communications
Weave Now Integrates with Neo
© BusinessWire
Centene Corp
INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Centene Corporation (CNC) Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
© BusinessWire
Eutelsat
Eutelsat to Deliver LEO Connectivity for UK Government Operations Worldwide
© BusinessWire
DoubleVerify
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of DoubleVerify
© BusinessWire
Colgate-Palmolive
Colgate-Palmolive Webcasts 2025 Second Quarter Earnings Conference Call August 1, 2025 – 8:30 a.m. ET
© BusinessWire
ZimVie
ZIMV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ZimVie Inc. Is Fair to Shareholders
© BusinessWire
Ellington Financial
Ellington Financial Reports Preliminary Results for Second Quarter 2025
© BusinessWire
Mineros
Mineros S.A. Announces David Splett as New Chief Financial Officer
© BusinessWire
Super Micro
Supermicro Schedules Conference Call and Webcast for Fourth Quarter and Fiscal Year 2025 Financial Results on August 5, 2025
© BusinessWire
Coursera
Coursera Appoints Grant Parsamyan as Chief Data Officer
© BusinessWire
Backblaze
Backblaze Fuels Open Cloud Revolution with Data Region Expansion, Doubling Down on High-Performance Storage for AI, High Performance Compute (HPC), and Media Workflows
© BusinessWire
Sunlink Health Systems
SunLink Health Systems, Inc Declares Special Cash Dividend Prior to with the Proposed Merger with Regional Health Properties, Inc.
© BusinessWire
Voyager Technologies
Voyager Announces Second Quarter 2025 Earnings Results Call
© BusinessWire
Mastercard
American Airlines and Mastercard Renew Partnership for Even More Rewarding Travel Experiences
© BusinessWire
F&F Co.
F&F Engages Goldman Sachs as Strategic Financial Advisor for Potential TaylorMade Acquisition
© BusinessWire
Helios Technologies
Helios Technologies Schedules Second Quarter 2025 Financial Results Release and Conference Call
© BusinessWire
Teradata
Teradata Named a Leader in Data Management for Analytics Platforms
© BusinessWire
iA Financial
iA Financial Group, iA American Warranty Group, American Amicable, and Vericity Donate $75,000 to Support Texas Flood Relief Efforts
© BusinessWire

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.

On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.

 

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S